On April 23, 2021, the Food and Drug Administration approved loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and […]
molecular design & engineering
On April 23, 2021, the Food and Drug Administration approved loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and […]